Literature DB >> 667495

Plasma clearance of neostigmine and pyridostigmine in the dog.

P R Baker, T N Calvey, K Chan, C M Macnee, K Taylor.   

Abstract

1 The pharmacokinetics of neostigmine and pyridostigmine was studied in conscious dogs by the use of a cross-over design. 2 Both neostigmine and pyridostigmine were cleared from plasma in a biexponential manner. 3 The apparent volume of distribution of pyridostigmine was invariably greater than that of neostigmine, and its fast disposition half-life was approximately three times longer. 4 The whole body clearance and the urinary elimination of pyridostigmine was approximately twice that of neostigmine. 5 The slow disposition half-life of pyridostigmine was approximately three times longer than that of neostigmine, suggesting that the longer duration of action of pyridostigmine is related to the differential clearance of the two quarternary amines from plasma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 667495      PMCID: PMC1668085          DOI: 10.1111/j.1476-5381.1978.tb07805.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  HUMAN TISSUE CHOLINESTERASES: RATES OF RECOVERY AFTER INHIBITION BY NEOSTIGMINE; MICHAELIS-MENTEN CONSTANTS.

Authors:  R J KITZ
Journal:  Biochem Pharmacol       Date:  1964-09       Impact factor: 5.858

2.  Carbamyl derivatives of acetylcholinesterase.

Authors:  I B WILSON; M A HARRISON; S GINSBURG
Journal:  J Biol Chem       Date:  1961-05       Impact factor: 5.157

3.  Antagonism of tubocurarine. III. Time course of action of pyridostigmin, neostigmine, and edrophonium in vivo and in vitro.

Authors:  C M SMITH; J C MEAD; K R UNNA
Journal:  J Pharmacol Exp Ther       Date:  1957-06       Impact factor: 4.030

4.  Pyridostigmine metabolism in man.

Authors:  S M Somani; J B Roberts; A Wilson
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

5.  Comparative times to peak effect and durations of action of neostigmine and pyridostigmine.

Authors:  R D Miller; L S Van Nyhuis; E I Eger; T S Vitez; W L Way
Journal:  Anesthesiology       Date:  1974-07       Impact factor: 7.892

6.  Plasma clearance of neostigmine and pyridostigmine in rats with ligated renal pedicles.

Authors:  P A Burdfield; T N Calvey
Journal:  Eur J Pharmacol       Date:  1973-11       Impact factor: 4.432

7.  The inhibition and reactivation of acetylcholinesterase.

Authors:  E B Wilson
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

8.  In vitro metabolism of neostigmine and pyridostigmine.

Authors:  P A Burdfield; T N Calvey; J B Roberts
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765

9.  A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma.

Authors:  K Chan; N E Williams; J D Baty; T N Calvey
Journal:  J Chromatogr       Date:  1976-05-26
  9 in total
  4 in total

1.  Pharmacokinetics and pharmacological effects of neostigmine in man.

Authors:  T N Calvey; M Wareing; N E Williams; K Chan
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

2.  Effects of neostigmine and pyridostigmine on serum cholinesterase activity.

Authors:  R K Mirakhur; T D Lavery; L P Briggs; R S Clarke
Journal:  Can Anaesth Soc J       Date:  1982-01

3.  Effects of neostigmine and pyridostigmine on serum cholinesterase activity.

Authors:  R K Mirakhur; R S Clarke; P S Collier
Journal:  Can Anaesth Soc J       Date:  1982-05

4.  Kinetics of intravenous pyridostigmine in man.

Authors:  T N Calvey; K Chan; A Dehghan; N E Williams
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.